Mustafa YILDIRIM, Cem PARLAK, Mustafa YILDIZ, Nurullah BÜLBÜLLER, Cem SEZER, Çetin KAYA, Dinç SÜREN

Primeri Bilinmeyen Nöroendokrin Tümörler: İki Olgu Sunumu ve Literatürün Gözden Geçirilmesi

Birçok organda bulunan nöroendokrin hücrelerden gelişen tümörlerler klinik seyir ve prognoz açısından birbirinden farklıdır. Bu hastaların %13’ünde tümörün primer odağı tespit edilememektedir. Nöroendokrin tümörler elektron mikroskopisi ile tespit edilebilen membrana bağlı intrastoplazmik nörosekretuar granüllerle karakterizedirler. Yaygın lenf nodu tutulumuna neden olabilen bu tümörler klinik olarak lenfoproliferatif hastalıklar ile karışabilmektedir. Bu yazımızda yaygın lenf nodu tutulumu ile prezente olan primeri bilinmeyen nöroendokrin tümörlü iki olgumuzu güncel literatür eşliğinde tartıştık

Neuroendocrine Tumors of Unknown Prmary Site: Two Case Reports and Review of The Literature

The tumor growing in neuroendocrine cells, which are present in many organs, vary in terms of clinical progress and prognosis. In 13% of these patients, the primary focus of the tumor cannot be identified. Neuroendocrine tumors are characterized by intracytoplasmic neurosecretory granules which are linked to the membrane that can be detected by electron microscopy. Likely to lead to extensive involvement of the lymph node, these tumors can be clinically confused with lymphoproliferative diseases. In this article, we discuss two cases of neuroendocrine tumors presented with extensive involvement of the lymph node of unknown primary, in the light of the existing literature

Keywords:

neuroendocrine tumor, cancer of unknown primary, lymphoproliferative,

PDF

___

Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol 2009; 36:6.

Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol. 2009 Feb;36(1):52-9

Furlan D, Bernasconi B, Uccella S, Cerutti R, Carnevali I, Capella C. Allelo types and ﬂuorescence insitu hybridization proŞles of poorly differentiated endocrine carcinomas of different sites. Clin Cancer Res.2005;11:1765-75

Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J.. Chemotherapy and role of the proliferation marker Ki-67 indigestive neuroendocrine tumors. Endocr Rel Cancer.2007;14:221-32

Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonaryneuroendocrine tumors. Clin Cancer Res.2008;14:1059-64.

Erickson LA, Papouchado B, Dimashkieh H, Zhang S, Nakamura N, Lloyd RV. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites. Endocr Pathol. 2004 Fall;15(3):247-52.

Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, et al. Is the new WHO classiŞcation of neuroendocrine tumours useful for selecting an appropriate treatment? AnnOncol.2005;16:1374-80

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010 ;39(6):707-12.

Keller, AR, Hochholzer, L, Castleman, B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 29:670.

Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978; 69:86.

Solcia E, Rindi G, Paolotti D, La Rosa S, Capella C, Fiocca R. Clinicopathological profile as a basis for classification of the endocrine tumors of the gastroenteropancreatic tract. Ann Oncol 1999;10:S9-15

Meko JB, Doherty GM, Siegel BA, Norton JA. Evulation somatostatin receptor scintigraphy for detecting neuroendocrine tumors Surgey 1996;120:975-983

Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006 1;24(22):3548-54.